Arch Biopartners is heading to $6, says iA Capital Markets

read

Post

iA Capital Markets analyst Chelsea Stellick is staying bullish on Canadian biotech company Arch Biopartners (Arch Biopartners Stock Quote, Charts, News, Analysts, Financials TSXV:ARCH), saying in a Tuesday report that the company is ready to ramp up its clinical development programs.

Read more.

Source: Cantech Letter

Related insights

Algonquin Power is still a pass, says iA Capital Markets

read

iA Capital Markets analyst Naji Baydoun is still skeptical about Algonquin Power & Utilities (Algonquin Power & Utilities Stock Quote, Charts, News, Analysts, Financials TSX:AQN), saying in a review of the company’s latest quarterly numbers that investors should wait to see how well the utility company fares on this year’s strategic priorities. Read more. Source: Cantech Letter
Buy Innergex in renewable power sector, says iA Capital Markets

read

iA Capital Markets analyst Naji Baydoun delivered an update on Friday on Innergex Renewable Energy (Innergex Renewable Energy Stock Quote, Charts, News, Analysts, Financials TSE:INE) where he reviewed the company’s just-released fourth quarter results, saying the company has a strong growth outlook and declining payout ratio. Read more. Source: Cantech Letter
Exchange Income Corp wins a target raise from iA Capital Markets

read

Organic and inorganic growth as well as higher margins look to be in the cards for Exchange Income Corp (Exchange Income Stock Quote, Charts, News, Analysts, Financials TSX:EIF), according to iA Capital Markets analyst Matthew Weekes. Read more. Source: Cantech Letter
Healthcare stocks are looking attractive, says iA Capital Markets

read

Investors should be gearing up for some movement in the biotech space, says iA Capital Markets analyst Chelsea Stellick, who released a Healthcare sector report on Wednesday where she provided updates on 17 stocks under coverage. Read more. Source: Cantech Letter
iA Capital Market stays bullish on Dialogue Health Technologies

read

iA Capital Markets analyst Chelsea Stellick keeps talking up Dialogue Health Technologies (Dialogue Health Technologies Stock Quote, Charts, News, Analysts, Financials TSX:CARE) in a Wednesday report to clients where she maintained a “Buy” rating on the stock. Read more. Source: Cantech Letter